Nanoparticles for immunotherapy
View Patent ↗Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics.
1. A nanoparticle composition comprising: an isolated collection of synthetic particles that comprise a synthetic polymer that comprises hydroxyl groups effective to activate complement as measurable by at least a 10-fold increase in C3a when the particles are incubated with human serum, wherein the collection has a mean particle diameter of about 10 nm to about 100 nm, and the particles are further associated with an antigen, with the isolated collection of synthetic particles being effective in the absence of adjuvants to induce T cell dependent humoral immunity in a patient against the antigen in vivo.
2. The composition of claim 1 , wherein the antigen is covalently bound to the particle.
3. The composition of claim 1 , wherein the isolated collection of particles is free of sequences of amino acids or sequences of saccharides that activate complement.
4. The composition of claim 1 , wherein the synthetic polymer comprises a hydrophobic portion that is adsorbed to a hydrophobic portion of a second biodegradable polymer that forms a core of the nanoparticle to thereby bind the synthetic polymer to the core with the hydroxyl groups being available for interaction to activate complement.
5. The composition of claim 4 , wherein the hydroxyl groups are the termini of the synthetic polymer, and wherein the synthetic polymer comprises polyalkylene oxide.
6. The composition of claim 4 , wherein the synthetic polymer is a copolymer of poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol).
7. The composition of claim 4 , wherein the second polymer is polypropylene sulfide.
8. The composition of claim 1 , wherein the particles are free of targeting ligands that specifically bind to a cell.
9. The composition of claim 1 , wherein the antigen is an antigen of a tumor for tumor immunotherapy or an antigen of an infectious disease.
10. The composition of claim 1 , with the particles further comprising a danger signal chosen from the group consisting of inflammatory cytokines and ligands for Toll-like receptors.
11. The composition of claim 1 , wherein the antigen is a polypeptide or glycopeptide antigen.
12. The composition of claim 1 , wherein the collection has a mean particle diameter of about 10 nm to about 50 nm.
13. The composition of claim 12 , wherein the particles are free of targeting ligands that specifically bind to a cell, the antigen is an antigen for tumor immunotherapy or infectious disease, and further comprising a danger signal chosen from the group consisting of inflammatory cytokines and ligands for Toll-like receptors.
14. The composition of claim 12 , wherein the synthetic polymer comprises an amphiphilic block copolymer of at least one hydrophobic block and at least one hydrophilic block, wherein the block copolymer self-assembles in aqueous solutions to form the particles, wherein the functional groups on the hydrophilic block provide the activation of complement.
15. The composition of claim 14 , wherein the hydrophilic block comprises polyethylene glycol terminated with the hydroxyl groups.
16. A method of making an immunotherapeutic composition of nanoparticles that generate antibodies in a patient against an antigen comprising emulsion polymerization of a first polymer with a second polymer that is the emulsifier used during the polymerization to make a collection of particles with a mean diameter of between 20 and 50 nm, choosing the second polymer to comprise hydroxyl functional groups that activate complement measurable by at least a 10-fold increase in C3a when the particles are incubated with human serum, and associating an immunotherapeutic antigen with the particles, with the antigen being chosen for the generation of antibodies by a patient against the antigen.
17. The method of claim 16 , wherein the first polymer is biodegradable.
18. A method of delivering an immunotherapeutic agent to stimulate an immune system of a patient, the method comprising
introducing into the patient a collection of synthetic particles that
activate complement in the patient,
comprise the immunotherapeutic agent, and
deliver the immunotherapeutic agent to antigen-presenting cells,
wherein
the particles comprise a first polymer that activates complement as measurable by at least a 10-fold increase in C3a when the particles are incubated with human serum,
the collection has a mean diameter from about 10 nm to about 50 nm,
and
the particles comprise a second polymer to which the first polymer is bound.
19. The method of claim 18 , wherein the second polymer is biodegradable.
20. The method of claim 18 , wherein the particles are free of cell-specific targeting ligands and are specifically targeted to antigen presenting cells in lymph nodes for delivery of the immunotherapeutic agent to the antigen-presenting cells.
21. A nanoparticle composition comprising:
an isolated collection of synthetic particles, wherein the collection has a mean diameter of about 10 nm to about 100 nm, wherein the particles comprise
hydroxyl groups effective to activate complement as measurable by at least a 10-fold increase in C3a when the particles are incubated with human serum, and
an immunosuppressant drug,
wherein the particles are further associated with an antigen for antigen-specific tolerance.
22. The composition of claim 21 , wherein the particles comprise an amphiphilic block copolymer of at least one hydrophobic block and at least one hydrophilic block, wherein the block copolymer self-assembles in aqueous solutions to form the particles.
23. The composition of claim 21 , wherein the collection has a mean particle diameter of about 10 nm to about 50 nm.
24. The method of claim 18 wherein the immunotherapeutic agent is an antigen chosen for generation of antibodies against the antigen.
25. The method of claim 24 wherein the antigen is chosen to be an antigen of a tumor for tumor immunotherapy or an antigen of an infectious disease and further comprising administration of the nanoparticles as needed to maintain a desired titer of antibodies.
26. The method of claim 18 , wherein the antigen is covalently bound to the particle.
27. The method of claim 18 , wherein the isolated collection of particles is chosen to be free of sequences of amino acids or sequences of saccharides that activate complement.
28. The method of claim 18 , wherein the nanoparticles comprise a hydrophobic core and a polymer that has a first hydrophobic portion that is adsorbed to the core and a second portion with the hydroxyl groups disposed to be available to activate complement.
29. The method of claim 18 , wherein the particles are free of targeting ligands that specifically bind to a cell.
30. The method of claim 18 wherein the immunotherapeutic agent comprises an immunosuppressant.
31. The method of claim 18 wherein the immunotherapeutic agent comprises an antigen for antigen-specific tolerance.